{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T09:10:08Z","timestamp":1794301808742,"version":"4.9.0"},"reference-count":53,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Angiotensin II is a recently introduced vasopressor, which has been available since 2017. The novelty and the relatively high cost of angiotensin II currently limit its broader application. It induces vasoconstriction by activating the renin\u2013angiotensin\u2013aldosterone system and is currently the sole vasopressor functioning through this pathway. Beyond vasoconstriction, angiotensin II also affects various other physiological processes. Current evidence supports its use in managing vasoplegic and cardiogenic shock in patients who are unresponsive to catecholamines and vasopressin. However, due to limited data, the optimal timing for initiating therapy with angiotensin II, strategies for combining it with other vasopressors, and strategies for its discontinuation remain unclear. Ongoing and planned studies aim to address some of these uncertainties. This article reviews the physiological and pathophysiological effects of angiotensin II, describes its pharmacology, and provides a narrative review of the current literature.<\/jats:p>","DOI":"10.3390\/medicina60091483","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T07:59:46Z","timestamp":1726041586000},"page":"1483","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Angiotensin II\u2014Real-Life Use and Literature Review"],"prefix":"10.3390","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1161-3577","authenticated-orcid":false,"given":"Andreja","family":"M\u00f6ller Petrun","sequence":"first","affiliation":[{"name":"Department of Anaesthesiology, Intensive Therapy and Pain Management, University Medical Centre Maribor, 2000 Maribor, Slovenia"},{"name":"Faculty of Medicine, University of Maribor, 2000 Maribor, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"Markota","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Maribor, 2000 Maribor, Slovenia"},{"name":"Medical Intensive Care Unit, University Medical Centre Maribor, 2000 Maribor, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1186\/s13054-022-04255-y","article-title":"A plea for personalization of the hemodynamic management of septic shock","volume":"26","author":"Cecconi","year":"2022","journal-title":"Crit. Care"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021","volume":"47","author":"Evans","year":"2021","journal-title":"Intensive Care Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1186\/s13054-021-03813-0","article-title":"Equilibrating SSC guidelines with individualized care","volume":"25","author":"Vincent","year":"2021","journal-title":"Crit. Care"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00134-023-07290-7","article-title":"Angiotensin II","volume":"50","author":"Bellomo","year":"2024","journal-title":"Intensive Care Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1177\/08850666221145864","article-title":"Angiotensin II for Vasodilatory Hypotension in Patients Requiring Mechanical Circulatory Support","volume":"38","author":"Wieruszewski","year":"2023","journal-title":"J. Intensive Care Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ccc.2018.11.002","article-title":"Classic and Nonclassic Renin-Angiotensin Systems in the Critically Ill","volume":"35","author":"Bitker","year":"2019","journal-title":"Crit. Care Clin."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/s13054-023-04739-5","article-title":"The alternative renin\u2013angiotensin system in critically ill patients: Pathophysiology and therapeutic implications","volume":"27","author":"Garcia","year":"2023","journal-title":"Crit. Care"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.peptides.2011.05.012","article-title":"New Insights and Perspectives on Intrarenal Renin-Angiotensin System: Focus on Intracrine\/Intracellular Angiotensin II","volume":"32","author":"Zhuo","year":"2011","journal-title":"Peptides"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2796.2008.01981.x","article-title":"Renin-angiotensin system revisited","volume":"264","author":"Fyhrquist","year":"2008","journal-title":"J. Intern. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Abassi, Z., Higazi, A.A.R., Kinaneh, S., Armaly, Z., Skorecki, K., and Heyman, S.N. (2020). ACE2, COVID-19 Infection, Inflammation, and Coagulopathy: Missing Pieces in the Puzzle. Front. Physiol., 11.","DOI":"10.3389\/fphys.2020.574753"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1357-2725(02)00271-6","article-title":"Inflammation and angiotensin II","volume":"35","author":"Suzuki","year":"2003","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Laghlam, D., Jozwiak, M., and Nguyen, L.S. (2021). Renin-Angiotensin-Aldosterone System and Immunomodulation: A State-of-the-Art Review. Cells, 10.","DOI":"10.3390\/cells10071767"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1152\/physrev.00036.2005","article-title":"Physiology of local renin-angiotensin systems","volume":"86","author":"Paul","year":"2006","journal-title":"Physiol. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13054-015-0802-3","article-title":"Angiotensin II in septic shock","volume":"19","author":"Takala","year":"2015","journal-title":"Crit. Care"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13054-018-1995-z","article-title":"Angiotensin in Critical Care","volume":"22","author":"Hall","year":"2018","journal-title":"Crit. Care Lond. Engl."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1152\/physrev.00038.2017","article-title":"Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology","volume":"98","author":"Forrester","year":"2018","journal-title":"Physiol. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0167-0115(96)02116-7","article-title":"Angiotensin II- and IV-induced changes in cerebral blood flow. Roles of AT1, AT2, and AT4 receptor subtypes","volume":"68","author":"Harding","year":"1997","journal-title":"Regul. Pept."},{"key":"ref_18","first-page":"111","article-title":"Angiotensin Receptors: Structure, Function, Signaling and Clinical Applications","volume":"1","author":"Singh","year":"2016","journal-title":"J. Cell Signal."},{"key":"ref_19","first-page":"567","article-title":"Angiotensin II-induced vasopressin release is mediated through alpha-1 adrenoceptors and angiotensin II AT1 receptors in the supraoptic nucleus","volume":"267","author":"Qadri","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1161\/01.CIR.96.11.4065","article-title":"Extracellular matrix remodeling in heart failure: A role for de novo angiotensin II generation","volume":"96","author":"Weber","year":"1997","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1124\/pr.114.010454","article-title":"International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli","volume":"67","author":"Karnik","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1524-6175.2005.05141.x","article-title":"Angiotensin receptor blockers: New considerations in their mechanism of action","volume":"8","author":"Sica","year":"2006","journal-title":"J. Clin. Hypertens. Greenwich Conn."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1152\/physrev.00023.2016","article-title":"The ACE2\/Angiotensin-(1-7)\/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7)","volume":"98","author":"Santos","year":"2018","journal-title":"Physiol. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13054-020-2733-x","article-title":"Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock","volume":"24","author":"Bellomo","year":"2020","journal-title":"Crit. Care Lond. Engl."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3892\/etm.2014.1566","article-title":"Severe sepsis: Low expression of the renin-angiotensin system is associated with poor prognosis","volume":"7","author":"Zhang","year":"2014","journal-title":"Exp. Ther. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"12531261","DOI":"10.1164\/rccm.201911-2172OC","article-title":"Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock. A Clinical Trial","volume":"202","author":"Bellomo","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13054-020-2743-8","article-title":"Vasoplegic syndrome following cardiothoracic surgery\u2014Review of pathophysiology and update of treatment options","volume":"24","author":"Busse","year":"2020","journal-title":"Crit. Care"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.kint.2020.07.047","article-title":"Impaired angiotensin II type 1 receptor signaling contributes to sepsis-induced acute kidney injury","volume":"99","author":"Leisman","year":"2021","journal-title":"Kidney Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s13054-022-04161-3","article-title":"Myocardial effects of angiotensin II compared to norepinephrine in an animal model of septic shock","volume":"26","author":"Garcia","year":"2022","journal-title":"Crit. Care Lond. Engl."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJMoa1704154","article-title":"Angiotensin II for the Treatment of Vasodilatory Shock","volume":"377","author":"Khanna","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/CCM.0000000000003092","article-title":"Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II","volume":"46","author":"Tumlin","year":"2018","journal-title":"Crit. Care Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1097\/CCM.0000000000002441","article-title":"Clinical Experience With IV Angiotensin II Administration: A Systematic Review of Safety","volume":"45","author":"Busse","year":"2017","journal-title":"Crit. Care Med."},{"key":"ref_33","unstructured":"(2019, September 02). Drug Trials Snapshots: GIAPREZA. FDA, Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trials-snapshots-giapreza."},{"key":"ref_34","unstructured":"(2024, June 10). Giapreza|European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/giapreza."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"R190","DOI":"10.1186\/cc8185","article-title":"Angiotensin II in experimental hyperdynamic sepsis","volume":"13","author":"Wan","year":"2009","journal-title":"Crit. Care Lond. Engl."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/CCM.0000000000002797","article-title":"Urinary Oxygenation as a Surrogate Measure of Medullary Oxygenation During Angiotensin II Therapy in Septic Acute Kidney Injury","volume":"46","author":"Lankadeva","year":"2018","journal-title":"Crit. Care Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1186\/s13054-014-0534-9","article-title":"Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): A pilot study","volume":"18","author":"Chawla","year":"2014","journal-title":"Crit. Care Lond. Engl."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13054-023-04446-1","article-title":"Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: An exploratory post-hoc analysis of the ATHOS-3 clinical trial","volume":"27","author":"Wieruszewski","year":"2023","journal-title":"Crit. Care Lond. Engl."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/0885066620972943","article-title":"A Multicenter Observational Cohort Study of Angiotensin II in Shock","volume":"37","author":"Smith","year":"2022","journal-title":"J. Intensive Care Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/SHK.0000000000002109","article-title":"A pilot study of angiotensin II as primary vasopressor in critically ill adults with vasodilatory hypotension: The ARAMIS study","volume":"59","author":"See","year":"2023","journal-title":"Shock"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.chest.2020.08.2074","article-title":"Angiotensin II Infusion for Shock: A Multicenter Study of Postmarketing Use","volume":"159","author":"Wieruszewski","year":"2021","journal-title":"Chest"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/anae.15802","article-title":"A double-blind randomised feasibility trial of angiotensin-2 in cardiac surgery","volume":"77","author":"Coulson","year":"2022","journal-title":"Anaesthesia"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.bja.2023.06.056","article-title":"Renin-angiotensin-aldosterone system dynamics after targeted blood pressure control using angiotensin II or norepinephrine in cardiac surgery: Mechanistic randomised controlled trial","volume":"131","author":"Coulson","year":"2023","journal-title":"Br. J. Anaesth."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrneph.2018.15","article-title":"Angiotensin-converting enzyme in innate and adaptive immunity","volume":"14","author":"Bernstein","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1002\/cphy.c120002","article-title":"The Non-Classical Renin-Angiotensin System and Renal Function","volume":"2","author":"Chappell","year":"2012","journal-title":"Compr. Physiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e2211370119","DOI":"10.1073\/pnas.2211370119","article-title":"Angiotensin II enhances bacterial clearance via myeloid signaling in a murine sepsis model","volume":"119","author":"Leisman","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Bryniarski, P., Nazimek, K., and Marcinkiewicz, J. (2022). Immunomodulatory Activity of the Most Commonly Used Antihypertensive Drugs\u2014Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031772"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1164\/rccm.202002-0339OC","article-title":"Norepinephrine Dysregulates the Immune Response and Compromises Host Defense during Sepsis","volume":"202","author":"Stolk","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_49","first-page":"3448","article-title":"A critical role for both CD40 and VLA5 in angiotensin II-mediated thrombosis and inflammation","volume":"32","author":"Senchenkova","year":"2018","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1172\/JCI117809","article-title":"Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis","volume":"95","author":"Vaughan","year":"1995","journal-title":"J. Clin. Investig."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/CCM.0000000000003544","article-title":"Renin as a Marker of Tissue-Perfusion and Prognosis in Critically Ill Patients","volume":"47","author":"Gleeson","year":"2019","journal-title":"Crit. Care Med."},{"key":"ref_52","first-page":"1002","article-title":"The Association Between Angiotensin II and Renin Kinetics in Patients After Cardiac Surgery","volume":"134","author":"Meersch","year":"2022","journal-title":"Anesth. Analg."},{"key":"ref_53","first-page":"165","article-title":"A Pilot Study of Renin-Guided Angiotensin-II Infusion to Reduce Kidney Stress After Cardiac Surgery","volume":"139","author":"Sadjadi","year":"2024","journal-title":"Anesth. Analg."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/9\/1483\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:53:57Z","timestamp":1760111637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/9\/1483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":53,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["medicina60091483"],"URL":"https:\/\/doi.org\/10.3390\/medicina60091483","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,11]]}}}